Novartis’ oral multiple sclerosis Gilenya could be on the European market in just three months after winning the backing of …
Sanofi-Aventis is to begin the first phase III study of an oral drug as an add-on to standard therapy in …
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns

